Young Kim

Creating Resources for Every American To Experiment with Artificial Intelligence Act of 2025 or the CREATE AI Act of 2025

This bill establishes a national program to provide U.S. researchers, educators, and students with access to artificial intelligence (AI) data, computational resources, educational tools and services, and testbeds.

The program, to be known as the National Artificial Intelligence Research Resource (NAIRR), must be established by the National Science Foundation (NSF) to improve U.S. AI research capacity and spur the strategic development of AI capabilities. NAIRR may accept and use donated resources from the private sector and federal agencies.

Those eligible to use NAIRR resources are (1) researchers, educators, and students based in the United States and affiliated with a U.S. institution of higher education, nonprofit, executive agency, or other specified entity; and (2) employees of U.S. executive agencies or federally funded research and development centers with a demonstrable mission need.

NSF must select a nongovernmental organization to operate NAIRR (i.e., an operating entity) through a competitive and transparent process. The operating entity must ensure that a significant percentage of the annual allotment of computational resources is provided to projects primarily focused on AI privacy, ethics, safety, security, risk mitigation, or trustworthiness. The operating entity must also establish minimum security requirements for all individuals interacting with NAIRR.

The operating entity may establish a fee schedule for access to NAIRR, which must include a free tier of access and must ensure that the primary purpose of NAIRR is to support research.

FDA Modernization Act 3.0

This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug.

The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications.

The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.

Protecting Our Courts from Foreign Manipulation Act

This bill limits third-party financing of civil litigation by foreign entities in federal courts and establishes related disclosure requirements.

The bill makes it unlawful for a foreign state or sovereign wealth fund to provide any monetary support for a civil action in which it is not a named party. The bill also makes it unlawful for any party or counsel to receive monetary support for civil litigation from a foreign state or sovereign wealth fund that is not a party.

The bill also prohibits third-party litigation funding agreements involving money from a foreign state or sovereign wealth fund in which someone other than named parties or counsel of record receives a payment that is contingent on the outcome or proceeds from the civil action or from any matter within a portfolio that includes the civil action.

The bill requires any party or counsel in a civil action to disclose the name of any foreign person, state, or sovereign wealth fund that has agreed to provide monetary support for the civil action, has a right to receive a payment contingent upon the outcome of the civil action, or has the right to receive payment that is contingent on proceeds from any matter within a portfolio that includes the civil action.

The bill also requires parties to produce the agreement creating a contingent right to payment.

These requirements apply to claims that are pending on or commenced after this bill's date of enactment.

Humane Cosmetics Act of 2025

This bill generally prohibits animal testing in the evaluation of cosmetic products, and it prohibits the sale or transport of cosmetics developed using animal testing, subject to civil penalties. These prohibitions begin one year after enactment.

The bill specifies exceptions to these prohibitions, including if such animal testing (1) is conducted outside the United States to comply with a foreign regulatory authority; (2) is pursuant to a finding by the Food and Drug Administration (FDA) that there are no nonanimal alternatives to test the safety of a potentially dangerous cosmetic product or ingredient; (3) is of a product or ingredient for a drug or device subject to regulation by the FDA; or (4) is required for a noncosmetic purpose pursuant to a state, federal, or foreign regulatory authority.

Further, evidence derived from animal testing conducted more than one year after the bill's enactment may not be used to establish the safety of a cosmetic product or ingredient that is regulated by the FDA, subject to limited exceptions.

This resolution expresses support for tax policies that support working families and recognizes the tax relief enacted as part of the 2025 reconciliation act.

This bill designates the facility of the United States Postal Service located at 1444 Main Street in Ramona, California, as the "Archie Moore Post Office Building".